The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34222
Abstract: Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease… read more here.
Keywords: clinical dilemma; jaki; inhibitor; myelofibrosis ... See more keywords
Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.256
Abstract: Statement of Purpose, Innovation, or Hypothesis Itacitinib is a JAK-1 inhibitor currently in phase III development for the treatment of acute and chronic graft versus host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily… read more here.
Keywords: pharmacokinetic analysis; population; itacitinib; population pharmacokinetic ... See more keywords
Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental hematology"
DOI: 10.1016/j.exphem.2021.06.004
Abstract: Targeting Januskinase (JAK) has revolutionized the treatment of myeloproliferative neoplasms. The JAK inhibitor ruxolitinib improved the outcome and quality of life of patients dramatically at the cost of increased risk of infections. As previously shown,… read more here.
Keywords: pacritinib; ruxolitinib pacritinib; jak inhibitor; dendritic cells ... See more keywords
Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
Sign Up to like & getrecommendations! Published in 2017 at "Neuroscience Letters"
DOI: 10.1016/j.neulet.2017.01.041
Abstract: Recent clinical trials suggest that patients with myelofibrosis can develop Wernicke's encephalopathy (WE) when treated with fedratinib, a specific Janus kinase-2 (JAK-2) inhibitor. To investigate this issue, we have examined (1) if fedratinib can produce… read more here.
Keywords: inhibitor; jak inhibitor; treatment; fedratinib lead ... See more keywords
Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01977
Abstract: The JAK kinases JAK1, JAK2, JAK3, and TYK2 play key roles in cytokine signaling. Activation of the JAK/STAT pathways is linked to many diseases involving the immune system, including atopic dermatitis. As systemic JAK inhibitor… read more here.
Keywords: atopic dermatitis; jak inhibitor; cee321; jak ... See more keywords
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.308
Abstract: Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal… read more here.
Keywords: inhibitor ruxolitinib; jak inhibitor; mice; calr ... See more keywords
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial *
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21037
Abstract: Chronic hand eczema (CHE) is a burdensome disease, and new well‐documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan‐Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was… read more here.
Keywords: chronic hand; hand eczema; jak inhibitor; inhibitor delgocitinib ... See more keywords
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Dermatology"
DOI: 10.1111/exd.13253
Abstract: This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐JAK2 in CLE skin samples… read more here.
Keywords: inhibitor ruxolitinib; ruxolitinib; jak inhibitor; ruxolitinib inhibits ... See more keywords
POS0669 HYPOGLYCAEMIA FOLLOWING JAK INHIBITOR TREATMENT IN DIABETES MELLITUS PATIENTS WITH RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.1851
Abstract: Background: Janus kinase (JAK) inhibitors are effective small molecular drugs for rheumatoid arthritis (RA) and other immune mediated inflammatory diseases (IMIDs). JAK inhibitors exert their immunosuppressive effects by suppressing the action of JAK, an intracellular… read more here.
Keywords: personal fees; jak; jak inhibitor; research ... See more keywords
A case of generalised pustular psoriasis with bullous pemphigoid showing spongiform pustule of Kogoj with eosinophils
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2021.4138
Abstract: EJD, vol. 31, n◦ 5, September-October 2021 The second case is a 23-year-old Japanese man with AD since infancy who was started on dupilumab due to insufficient control of skin lesions by topical corticosteroids (EASI… read more here.
Keywords: th17; jak inhibitor; jak; psoriasis ... See more keywords
Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.
Sign Up to like & getrecommendations! Published in 2022 at "Current medicinal chemistry"
DOI: 10.2174/1568026622666220307124142
Abstract: Janus Kinase (JAK), a nonreceptor protein tyrosine kinase, has emerged as an excellent target through research and development since its discovery in the 1990s. As novel small-molecule targeted drugs, JAK inhibitor drugs have been successfully… read more here.
Keywords: inhibitor drugs; kinase; jak; jak inhibitor ... See more keywords